Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2026
Reporting Period: Single event date (February 6, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on NYSE American LLC. This filing serves as a Regulation FD disclosure to make an updated corporate presentation available to the public.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a corporate presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The sole material event reported is the release of an updated presentation (Exhibit 99.1) on the Company's website.
Guidance, Outlook, and Risks
Management Commentary: The filing references an updated presentation furnished as Exhibit 99.1, which likely contains management's outlook and strategic updates, but the content of that presentation is not included in the text of this report.
Legal Disclaimers: The Company explicitly states that the information in this Item 7.01 disclosure is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated. The Company makes no admission as to the materiality of the information solely by reason of Regulation FD.
Investor Verification Checklist
- Review Exhibit 99.1 (the updated presentation) for specific details on clinical progress, financial outlook, and strategic initiatives.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol (CLDI) and exchange (NYSE American LLC) for current market data.
- Note that this filing does not contain financial data; refer to the most recent 10-K or 10-Q for audited financial metrics.